Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· December 16, 2025

Marvell and Chipotle have been highlighted as Zacks Bull and Bear of the Day

View original at finance.yahoo.com
Marvell and Chipotle have been highlighted as Zacks Bull and Bear of the Day For Immediate Release Chicago, IL – December 16, 2025 – Zacks Equity Research shares Marvell Technology MRVL, as the Bull of the Day and Chipotle Mexican Grill CMG, as the Bear of the Day…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Roughly 40% of sales coming from younger guests under $100K who face wage and debt pressures, weighing on dining frequency

    80% confidence
  • Revenue contributions from Celestial AI expected to begin in second half of fiscal 2028, with path to $500 million run rate by fiscal 2028 and $1 billion by fiscal 2029

    80% confidence
  • Full year revenue growth expected to exceed 40% with data center revenue accelerating into next year

    80% confidence
  • Buy rating on MRVL with $114 price target

    80% confidence
  • Chipotle faces near-term headwinds despite long-term brand strength. Slowing same-store sales, margin pressure, and declining analyst estimates highlight challenges of sustaining growth in high-cost, high-valuation environment

    80% confidence
  • Buy rating on MRVL with $130 price target, 50% higher than current trading levels

    80% confidence
  • Marvell checks key boxes investors want: accelerating earnings, rising estimates, strong momentum, and deep exposure to long duration AI and data center spending

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com